Verbakel, Jan Y
Matheeussen, Veerle
Loens, Katherine
Kuijstermans, Mandy
Goossens, Herman
Ieven, Margareta
Butler, Christopher C
Funding for this research was provided by:
Seventh Framework Programme (HEALTH-F3-2013-602525)
Roche Molecular Diagnostics (LIAT-IIS-007)
Article History
Received: 8 January 2020
Accepted: 4 March 2020
First Online: 14 March 2020
Compliance with ethical standards
:
: Dr. Butler reports receiving advisory board fees from Roche Molecular Systems and Dr. Butler and Dr. Verbakel report receiving grant support from Roche Molecular Diagnostics. No other potential conflict of interest relevant to this article was reported.
: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee (NRES Committee South Central (Oxford B) approval and Clinical Trial Authority (CTA) approval by The Medicines and Healthcare products Regulatory Agency was obtained and all participating countries gained national Research Ethics Committee and CTA approval as required) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: We included a selection of swabs taken from patients presenting to primary care with symptoms of ILI, willing to participate in the ALIC<sup>4</sup>E trial, who met the inclusion criteria and gave written informed consent. [CitationRef removed]